Jasper Therapeutics, Inc.
JSPRWDrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
Jasper M&A / Acquisition
Filed: 2026-07-17 AccNo: 0001213900-26-078887 Size: 17 MB Item 1.01: Entry into a Material Definitive Agreement Item 2.01: Completion of Acquisition or Disposition of Assets Item 3.02: Unregistered Sales of Equity Securities Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Source| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Briquilimab | Phase 2 | Urticaria Chronic | - | - |
Frequently asked questions
What is in Jasper Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Jasper Therapeutics, Inc.'s (JSPRW) pipeline across Phase 2. Its lead program is Briquilimab (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Jasper Therapeutics, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Jasper Therapeutics, Inc. (JSPRW) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track JSPRW biotech catalysts?→
Add JSPRW to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Jasper Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.